Xylazine

The opioid epidemic in the US has taken a new turn as a new synthetic cutting agent, Xylazine, has emerged as a cause for concern. Xylazine is an animal tranquilizer and is being used to dilute opioids like heroin, leading to outbreaks of skin infections and overdoses in major cities across the country.

What is Xylazine?

Xylazine is a sedative commonly used by veterinarians to calm animals during medical procedures. It is not approved for human use in the US, but it has been used as a recreational drug in some countries. Xylazine produces a state of sedation and a feeling of dissociation in humans, making it attractive for recreational use.

The rise of “Tranq Dope”

The use of Xylazine as a cutting agent for opioids like heroin has given rise to a new drug called “Tranq Dope.” This dangerous mix of Fentanyl and Xylazine is being sold for just a few dollars per bag in the country. It is highly addictive and can cause severe skin infections, abscesses, and other health problems.

The impact of Xylazine on the opioid epidemic

Xylazine has emerged as a major cause for concern in the US opioid epidemic. It is being used as a cheap alternative to other cutting agents like fentanyl, and its widespread use has led to a surge in overdoses and infections. People who use Xylazine-tainted drugs often develop large, open wounds that can take months to heal. These wounds are prone to bacterial infections and can be life-threatening if left untreated.

Efforts to combat Xylazine use

Law enforcement agencies are taking steps to combat the use of Xylazine in the US. The Drug Enforcement Administration (DEA) has issued warnings about the dangers of Xylazine and has listed it as a Schedule IV controlled substance. The DEA has also launched several initiatives to target the sources of Xylazine in the US.

In addition to law enforcement efforts, public health officials are also working to combat the impact of Xylazine on the opioid epidemic. The Centers for Disease Control and Prevention (CDC) has issued guidance on the treatment of skin infections caused by Xylazine-tainted drugs. The CDC has recommended that patients receive antibiotics and wound care to prevent the spread of infection.